Latest news with #Stereotaxis
Yahoo
13-05-2025
- Business
- Yahoo
Stereotaxis Inc (STXS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Release Date: May 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Stereotaxis Inc (STXS) reported a solid 9% year-over-year revenue growth for Q1 2025. The company is seeing commercial progress with its differentiated EP catheters, including the recently approved Magic catheter in Europe. Recurring revenue growth is driven by the Mapi family of diagnostic EP catheters, with sales in the US growing 30% sequentially. Stereotaxis Inc (STXS) received European approval for the Magic ablation catheter, with initial sales expected to ramp up significantly. The company is preparing for the first commercial installation of Genesis X, which is expected to drive robotic system growth. Structural challenges of the old product ecosystem remain a significant headwind for Stereotaxis Inc (STXS). The process of getting catheters adopted is gradual, requiring administrative efforts and clinical support. Recurring revenue gross margins are impacted by acquisition-related accounting, temporarily reducing disposable margins. Operating loss and net loss increased compared to the previous year, with operating expenses rising due to acquisition-related costs. Uncertainty in the Chinese market and macroeconomic conditions could impact potential revenue from Genesis systems. Warning! GuruFocus has detected 8 Warning Signs with STXS. Q: Can you provide more details on the backlog for Genesis and Genesis X systems in the US and Europe, and how the capital equipment environment is affecting these? A: David Fischer, CEO: The capital environment varies by region. In the US, the ecosystem is less advanced due to pending approvals for Genesis X and related catheters. Interest exists, but actionable steps await regulatory clearance. In Europe, there's a robust pipeline for both Genesis and Genesis X, with some hospitals already planning for Genesis. In China, despite macroeconomic uncertainties, there's potential upside with recent regulatory approval. Q: How is the Magic RF ablation catheter performing in Europe, and what is the expected scaling over the next quarters? A: David Fischer, CEO: The reception has been positive, with usage across a variety of procedures. The catheter is predominantly used in complex cases like VTs and PVCs. We expect Magic to reach a $1 million quarterly run rate in Europe by year-end, with full market conversion anticipated over two years. Q: What are the ordering patterns for the 20% of European customers using Magic, and how is the adoption process? A: David Fischer, CEO: Initial orders typically consist of 5-10 catheters, with hospitals testing them before full adoption. Feedback has been positive, and repeat orders are starting. The adoption process involves hospital reviews and national approvals, which is progressing well. Q: What is the status of the Magic catheter's FDA approval in the US, and what remains in the submission process? A: David Fischer, CEO: The FDA review is ongoing, with detailed questions being addressed. Most supplementary tests are complete, and clinical data from European studies are being shared with the FDA. An on-site audit may be required, but the timeline for approval remains realistic for the second half of the year. Q: How do you envision the case mix for robotic magnetic navigation cardiac ablation procedures evolving with the expanded catheter portfolio? A: David Fischer, CEO: The focus remains on complex cases like VTs, PVCs, and congenital patients, where robotic navigation offers the most value. While there's potential to expand into atrial ablations, the current strategy is to capitalize on the significant growth opportunity within complex ablations. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Business Insider
13-05-2025
- Business
- Business Insider
Roth MKM Sticks to Its Buy Rating for Stereotaxis (STXS)
In a report released yesterday, Jason Wittes from Roth MKM reiterated a Buy rating on Stereotaxis (STXS – Research Report), with a price target of $5.00. The company's shares closed yesterday at $2.07. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Wittes covers the Healthcare sector, focusing on stocks such as Globus Medical, Allurion Technologies, and Monogram Orthopaedics Inc. According to TipRanks, Wittes has an average return of 2.7% and a 48.06% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stereotaxis with a $4.67 average price target, which is a 125.60% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target. STXS market cap is currently $183.1M and has a P/E ratio of -7.17. Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STXS in relation to earlier this year. Most recently, in March 2025, Isaac Paul J , a Director at STXS bought 38,000.00 shares for a total of $68,780.00.
Yahoo
13-05-2025
- Business
- Yahoo
Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.05 per share when it actually produced a loss of $0.09, delivering a surprise of -80%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Stereotaxis , which belongs to the Zacks Medical - Instruments industry, posted revenues of $7.47 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 6.74%. This compares to year-ago revenues of $6.88 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Stereotaxis shares have lost about 6.6% since the beginning of the year versus the S&P 500's decline of -3.8%. While Stereotaxis has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Stereotaxis: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.07 on $7.95 million in revenues for the coming quarter and -$0.26 on $34 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Lucid Diagnostics Inc. (LUCD), has yet to report results for the quarter ended March 2025. The results are expected to be released on May 14. This company is expected to post quarterly loss of $0.09 per share in its upcoming report, which represents a year-over-year change of +57.1%. The consensus EPS estimate for the quarter has been revised 40% higher over the last 30 days to the current level. Lucid Diagnostics Inc.'s revenues are expected to be $1.3 million, up 30% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stereotaxis Inc. (STXS) : Free Stock Analysis Report Lucid Diagnostics Inc. (LUCD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
22-04-2025
- Business
- Yahoo
Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025
ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. What: Stereotaxis first quarter 2025 financial results conference call When: Monday, May 12, 2025, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number: To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 4794777. Webcast: To access the live and replay webcast, please visit the investor relations section of Stereotaxis' website at Call Replay: A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here. Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit CONTACT: Investor Contacts: David L. Fischel Chairman and Chief Executive Officer Kimberly Peery Chief Financial Officer 314-678-6100 Investors@
Yahoo
21-04-2025
- Business
- Yahoo
Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025
GenesisX pairs clinical capability with broad accessibility in surgical robotics ST. LOUIS, April 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced today it will host a live demonstration of the GenesisX Robotic System at this year's Heart Rhythm Symposium (HRS), taking place April 24 – 27 in San Diego, CA. This marks the first live, public demonstration of GenesisX, offering a glimpse to HRS attendees into the robot's revolutionary clinical capabilities and 'weekend' installation. GenesisX represents the latest advance in endovascular surgical robotics, building upon the proven benefits of Robotic Magnetic Navigation while significantly enhancing accessibility for healthcare providers. The system features a compact and efficient design, incorporating magnetic shielding into its structure to eliminate the need for room-based shielding, reducing infrastructure requirements. GenesisX operates on standard 120/230V power, requires no structural anchoring, and features an 80% smaller system cabinet that conveniently fits under an operating room table. The system's smaller and lighter design enhances workflow efficiency while maintaining the highest standards in speed and responsiveness. Stereotaxis will be located at Booth 1034 and will be featured during several events throughout the congress, including: Stereotaxis Investor Technology Demonstration: Friday April 25th at 12:00 PM PDT Joint Session with Africa Heart Rhythm Association on leveraging telerobotics to advance care in underserved communities: Saturday April 26th at 2:45 PM PDT Joint Session of HRS & Society for Cardiac Robotic Navigation (SCRN): April 27th at 12:45 PM PDT 'We are thrilled to bring GenesisX to HRS and allow the electrophysiology community to experience firsthand this cutting-edge innovation along with our expanding portfolio of proprietary catheters and digital technologies,' said David Fischel, Stereotaxis Chairman and CEO. 'We look forward to engaging with the electrophysiology community at HRS, who, together with us, are pioneering the frontiers of medicine.' GenesisX obtained CE Mark approval in Europe in 2024 and is currently under review for FDA 510(k) clearance in the United States. In addition to GenesisX, Stereotaxis will showcase its portfolio of compatible EP and vascular catheters, including the Map-iT™, MAGiC™, and EMAGIN™ product lines, as well as its advanced Synchrony™ and SynX™ digital lab technologies. If you are interested in a meeting to learn more about GenesisX or other Stereotaxis technology, please contact info@ Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe', "estimate', "project', "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled. Stereotaxis Contacts:David L. FischelChairman and Chief Executive Officer Kimberly PeeryChief Financial Officer 314-678-6100Investors@ in to access your portfolio
